Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06500273 · ClinicalTrials.gov registry record · Phase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Phase 2 study of Large B-cell Lymphoma, sponsored by Allogene Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06500273: Recruiting Phase 2 study of Large B-cell Lymphoma, sponsored by Allogene Therapeutics.
NCT06500273 is a Phase 2 study of Large B-cell Lymphoma that is actively recruiting participants, run by Allogene Therapeutics. The registered enrollment target is 250 participants, above the 150-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06500273, a Phase 2 study of Large B-cell Lymphoma, is actively recruiting participants, sponsored by Allogene Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC cemacabtagene ansegedleucel
- DEVICE Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- City of Hope - Duarte
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Los Angeles - Los Angeles
- University of California, Davis Comprehensive Cancer Center - Sacramento
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
- Advent Health Cancer Institute - Orlando
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Arkansas
- Genesis Cancer and Blood Institute - Hot Springs
Colorado
- Rocky Mountain Cancer Centers - Denver
Delaware
- Medical Oncology Hematology Consultants - Newark
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Georgia
- Augusta University Georgia Cancer Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2032-12 |
| Phase | Phase 2 |
What NCT06500273 shows while recruiting
NCT06500273 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 150-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT06500273 names 20 study sites across 11 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06500273 about?
NCT06500273 is a clinical study titled "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL". This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ In...
What is the current status of trial NCT06500273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2024-06-18. Estimated completion is 2032-12.
What conditions does trial NCT06500273 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06500273?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), cemacabtagene ansegedleucel (GENETIC), Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ (DEVICE).
Who is sponsoring clinical trial NCT06500273?
This trial is sponsored by Allogene Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06500273 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06500273's enrollment target sits among peer trials
250 6th of 28 higher than 23 of 28 other Large B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Large B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
CAR-T Followed by Bispecific Antibodies
RECRUITING · Phase 2
-
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI